Publication | Closed Access

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

UrologyGenitourinary CancerMedicinePharmacologyClinical TrialsPharmacotherapyCancer TreatmentProstatic DiseaseOncologyMolecular Oncology